

# Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant *Staphylococcus aureus* Bacteremia and Endocarditis: A Randomized Clinical Trial

Miquel Pujol,<sup>1,a</sup> José-María Miró,<sup>2,a</sup> Evelyn Shaw,<sup>1</sup> Jose-María Aguado,<sup>3</sup> Rafael San-Juan,<sup>3</sup> Mireia Puig-Asensio,<sup>4</sup> Carles Pigrau,<sup>4</sup> Esther Calbo,<sup>5</sup> Miguel Montejo,<sup>6</sup> Regino Rodríguez-Álvarez,<sup>6</sup> María-Jose Garcia-Pais,<sup>7</sup> Vicente Pintado,<sup>8</sup> Rosa Escudero-Sánchez,<sup>8</sup> Joaquín Lopez-Contreras,<sup>9</sup> Laura Morata,<sup>2</sup> Milagros Montero,<sup>10</sup> Marta Andrés,<sup>11</sup> Juan Pasquau,<sup>12</sup> María-del-Mar Arenas,<sup>12</sup> Belén Padilla,<sup>13</sup> Javier Murillas,<sup>14</sup> Alfredo Jover-Sáenz,<sup>15</sup> Luis-Eduardo López-Cortes,<sup>16</sup> Graciano García-Pardo,<sup>17</sup> Oriol Gasch,<sup>18</sup> Sebastian Videla,<sup>19</sup> Pilar Hereu,<sup>19</sup> Cristian Tebé,<sup>20</sup> Natalia Pallarès,<sup>20</sup> Mireia Sanllorente,<sup>19</sup> María-Ángeles Domínguez,<sup>21</sup> Jordi Càmara,<sup>21</sup> Anna Ferrer,<sup>22</sup> Ariadna Padullés,<sup>22</sup> Guillermo Cuervo,<sup>1</sup> and Jordi Carratalà<sup>1,a</sup>; for the MRSA Bacteremia (BACSARM) Trial Investigators

<sup>1</sup>Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge, University of Barcelona, Barcelona, Spain, <sup>2</sup>Department of Infectious Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques Agust Pi i Sunyer, University of Barcelona, Barcelona, Spain, <sup>3</sup>Department of Infectious Diseases, Hospital Universitario 12 Octubre, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain, <sup>4</sup>Department of Infectious Diseases, Hospital Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain, <sup>5</sup>Infectious Diseases Unit, Hospital Universitari Mútua de Terrassa, Fundació Docència i Recerca Mútua de Terrassa, Universitat Internacional de Catalunya, Barcelona, Spain, <sup>6</sup>Department of Infectious Diseases, Hospital Universitario Cruces, Biocruces Bizkaia, Bilbao, Spain, <sup>7</sup>Infectious Diseases Unit, Hospital Lucus Augusti, Instituto de Investigación Sanitaria de Santiago de Compostela, Lugo, Spain, <sup>8</sup>Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria, Madrid, Spain, <sup>9</sup>Department of Infectious Diseases, Hospital Universitari de Sant Pau, Institut d'Investigació Biomèdica de Sant Pau, Barcelona, Spain, <sup>10</sup>Department of Infectious Diseases, Hospital del Mar, Institut de Recerca Hospital del Mar, Barcelona, Spain, <sup>11</sup>Infectious Disease Unit, Consorci Sanitari de Terrassa, Terrassa, Spain, <sup>12</sup>Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Sanitaria Granada, Granada, Spain, <sup>13</sup>Department of Clinical Microbiology and Infectious Diseases, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, <sup>14</sup>Department of Internal Medicine, Hospital Universitari Son Espases, Fundació Institut d'Investigació Sanitària Illes Balears, Mallorca, Spain, <sup>15</sup>Territorial Unit of Nosocomial Infection, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, Lleida, Spain, <sup>16</sup>Department of Infectious Diseases, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla, Sevilla, Spain, <sup>17</sup>Department of Internal Medicine, Hospital Universitari Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain, <sup>18</sup>Department of Infectious Diseases, Consorci Sanitari Hospital Parc Taulí, Fundació Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain, <sup>19</sup>Department of Clinical Pharmacology, Institut Investigacions Biomèdiques de Bellvitge, Clinical Research and Clinical Trials Unit, Plataforma Spanish Clinical Research Network, Barcelona, Spain, <sup>20</sup>Biosstatistics Unit, Institut Investigacions Biomèdiques de Bellvitge, L'Hospitalet de Llobregat, L'Hospitalet del Llobregat, Spain, <sup>21</sup>Department of Microbiology and Parasitology, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge, University of Barcelona, Barcelona, Spain, and <sup>22</sup>Department of Pharmacy, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge, University of Barcelona, Barcelona, Spain

(See the Editorial Commentary by Karchmer on pages 1526–8.)

**Background.** We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia and endocarditis.

**Methods.** A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy.

**Results.** Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93–1.8];  $P = .135$ ). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients;  $P = .003$ ) and lower complicated bacteremia (16.2% vs 32.1%;  $P = .022$ ). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone ( $P = .018$ ).

**Conclusions.** Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.

**Clinical Trials Registration.** NCT01898338.

**Keywords.** MRSA; bacteremia; daptomycin; fosfomycin; clinical trial.

Received 24 February 2020; editorial decision 9 July 2020; accepted 27 July 2020; published online July 29, 2020.

<sup>a</sup>M. P., J.-M. M., and J. C. contributed equally to this work.

Correspondence: M. Pujol, Department of Infectious Diseases, Hospital Universitari de Bellvitge, Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain (mpujol@bellvitgehospital.cat).

Clinical Infectious Diseases® 2021;72(9):1517–25

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com  
DOI: 10.1093/cid/ciaa1081

Bacteremia due to methicillin-resistant *Staphylococcus aureus* (MRSA) is a major healthcare problem worldwide [1, 2]. Microbiological failures including persistent and recurrent infection remain a major problem in the management of patients with MRSA bacteremia and endocarditis [3]. The persistently high mortality rate in MRSA bacteremia, ranging from 13% to 30%, is a matter of concern [4–6]. A major factor contributing to these adverse outcomes is the limited efficacy of the current standard antibiotic therapy with either vancomycin or daptomycin [7].

Vancomycin is the agent for which the greatest cumulative clinical experience is available for the treatment of MRSA bacteremia and endocarditis [8, 9]. Compared to  $\beta$ -lactams, vancomycin has relatively slow bacterial killing, poor tissue penetration, and potential for toxicity, all of which may be responsible for the clinical failures reported [10]. The use of vancomycin plus  $\beta$ -lactam therapy and adjunctive therapy with rifampicin to improve outcomes has proved unsatisfactory, providing little or no overall benefit over standard antibiotic therapy and increasing toxicity [11–13]. In a significant randomized trial [14], daptomycin at a dose of 6 mg/kg once daily was not inferior to standard therapy for the treatment of *S. aureus* bacteremia and endocarditis. Nevertheless, the emergence of resistant strains and subsequent therapeutic failures using a once-daily dose of 6 mg/kg of daptomycin has led to the use of higher doses (8–10 mg/kg once daily) in some centers [7]. Despite the use of high doses, treatment failures due to persistent or relapsing infections have been reported [15]. Therefore, more effective strategies for the treatment of serious staphylococcal infections are urgently needed.

The combination of daptomycin and fosfomycin is an appealing strategy for the treatment of MRSA bacteremia. Fosfomycin has gained attention due to its broad spectrum and bactericidal activity against drug-resistant bacteria, including MRSA [16]. Whereas daptomycin disrupts the cell membrane synthesis of *S. aureus* [17], fosfomycin presents bactericidal activity by inhibiting an early stage of peptidoglycan synthesis [16]. Because daptomycin and fosfomycin have different mechanisms of action, they have a synergistic and rapid bactericidal effect, and no cross-resistance has been observed between the drugs [18]. This synergistic activity may be explained by fosfomycin PBP-1 inhibition [19, 20] and by its ability to modify cell-wall protein composition [21].

In a rabbit model of experimental endocarditis, the combination of daptomycin and fosfomycin proved to be synergistic and rapidly bactericidal against MRSA [22]. Data from small series of patients have shown that the combination of fosfomycin with either  $\beta$ -lactams or daptomycin was superior to standard antibiotic therapy for MRSA bacteremia [23, 24]. However, no randomized trials comparing the efficacy and safety of the

combination of daptomycin plus fosfomycin vs daptomycin monotherapy for treatment of MRSA bacteremia have been performed to date.

We designed the current randomized multicenter trial to test the hypothesis that daptomycin plus fosfomycin achieves higher treatment success than daptomycin alone in hospitalized adults with MRSA bacteremia and native valve endocarditis.

## METHODS

### Study Design and Setting

We performed a randomized (1:1), multicenter, phase 3, superiority, open-label and parallel-group clinical trial of adult inpatients with MRSA bacteremia at 18 Spanish hospitals. Participants were recruited between December 2013 and November 2017. The ethics committee at each participating center approved the study protocol. The trial was conducted in agreement with the Declaration of Helsinki, the guidelines for Good Clinical Practice, and Spanish regulatory requirements. This academic trial is registered with ClinicalTrials.gov NCT01898338, and the protocol has been published elsewhere [25].

### Participants

Patients aged  $\geq 18$  years with MRSA bacteremia indicated by 1 or more positive blood cultures within the last 72 hours before randomization and with symptoms and signs of infection were eligible for the study. Patients or authorized representatives provided written informed consent. Exclusion criteria included life expectancy  $\leq 24$  hours, polymicrobial bacteremia, pneumonia as a source of bacteremia, prosthetic valve endocarditis, severe end-stage liver disease (Child-Pugh class C), New York Heart Association functional classification III/IV, prior history of eosinophilic pneumonia, any clinical condition that required additional antibiotic therapy active against MRSA, or allergy to daptomycin or fosfomycin.

### Randomization and Masking

Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or to receive 10 mg/kg of daptomycin intravenously daily, between 10 and 14 days for uncomplicated bacteremia and between 28 and 42 days for complicated bacteremia. A centralized electronic computer randomization schedule was developed by the Catalan Institute of Pharmacology. The randomization was performed in computer-generated variable blocks ranging from 4 to 8 patients per center, to conceal the sequence until the intervention was assigned. The code numbers for eligible patients were assigned in ascending sequential order. The allocation list was stored at the Catalan Institute of Pharmacology. At each

participating hospital, patients who provided written informed consent and met the study criteria were randomized by investigators, who obtained the assigned treatment and code number from a computer-assisted website.

### Procedures

Daptomycin (Cubicin, Merck Sharp & Dohme B.V., Haarlem, the Netherlands) was administered intravenously by a 30-minute infusion once a day, and fosfomicin (Fosfocina, ERN S.A., Barcelona, Spain), was administered intravenously by at least one 60-minute infusion every 6 hours. Antibiotic dosage was adjusted according to creatinine clearance [25].

Patients were evaluated by researchers at inclusion, day 3, day 7, and end of therapy (EOT), and at the test of cure (TOC) visit 6 weeks after EOT. Blood cultures were obtained at day 3, day 7 (when positive at day 3), EOT, and TOC. Moreover, blood cultures and biochemistry analyses were performed whenever it was considered necessary by the attending physicians and/or researchers, according to the patient's clinical evolution. Echocardiograms were performed at the discretion of the attending physicians. Removal of pacemaker was not specifically recorded, but it was the standard of care when considered the source of bacteremia in all of the participating centers. Definitions of persistent, recurrent, complicated MRSA bacteremia, and endocarditis are provided in the [Supplementary Appendix](#) [26, 27].

### Outcomes and Measurements

The primary endpoint was treatment success at TOC (6 weeks after EOT). Treatment success was considered when patient was alive and had resolution of clinical manifestations of infection and negative blood cultures at TOC after completion of therapy. Treatment failure was considered in any of the following situations: lack of clinical improvement at day 3 or later after the start of therapy, persistent MRSA bacteremia at day 7 or later, premature discontinuation of therapy due to adverse events (AEs) or based on clinical judgment, recurrent MRSA bacteremia before or at TOC, additional antimicrobial therapy active against MRSA administered before TOC, lack of blood cultures obtained at TOC, and/or death due to any cause before TOC. Only patients without treatment failure could have treatment success. For analysis purposes, patients lost to follow-up (with missing TOC data) were classified as treatment failure.

The secondary endpoints were MRSA bacteremia at day 3, day 7, and/or at TOC; microbiological failure; complicated bacteremia; AEs leading to treatment discontinuation, and mortality due to any cause at day 7 and at TOC. Microbiological failure was considered in the case of persistent bacteremia, recurrent bacteremia, and the emergence of resistance to study drugs during treatment.

Primary and secondary endpoints were assessed by study investigators in the modified intention-to-treat population. A systematic, prioritized, risk-based approach to monitor AEs was developed to ensure that the trial was conducted, recorded, and reported according to good clinical practices [28]. AEs were recorded in all patients who received at least 1 dose of the study medication. Clinical laboratory tests, vital signs, and other safety assessments were performed at scheduled visits. An independent data and safety monitoring committee was established to review data when half of the sample had been recruited. Mortality and serious AEs leading to discontinuation of therapy were considered key safety parameters. After a safety monitoring meeting performed on 25 May 2016, no significant differences in serious events between groups were detected, and a formal recommendation of continuing the study was established by the independent data and safety monitoring committee.

Microbiological methods are detailed in the [Supplementary Appendix](#).

### Statistical Analysis

Assuming a level of treatment success of 60% among patients receiving daptomycin alone at TOC, a sample size of 103 patients per group was calculated to reject the null hypothesis of equal effect, with a power of 80% and a significance level of 5%, for a 20% difference in treatment success among patients receiving fosfomicin plus daptomycin. A 20% dropout rate was anticipated. In November 2017, the number of recruited patients was 167 and the dropout rate was <5%. Considering the low dropout rate and the time elapsed since the trial was initiated, the study committee decided to recalculate the sample size. Thus, a size of 81 patients per arm was considered enough to find significant differences of 20% between arms with a power of 80% and an  $\alpha$  risk of .05. With this additional information, the trial was closed when 167 patients had been enrolled and followed up. Patients who failed to continue in the study trial because they were randomized in error or received <1 day of antibiotic treatment were considered dropouts. As previously stated, study outcomes were assessed in the modified intention-to-treat population, which included all appropriately randomized patients according to the study inclusion criteria who received  $\geq 24$  hours of antibiotic therapy. Main efficacy analyses and the proportion of treatment success at TOC were compared between groups using a 2-sided  $\chi^2$  test. Relative risk for study outcomes were calculated and reported with 95% confidence intervals (CIs). The homogeneity of the treatment effect was tested in several subgroups defined in the statistical analysis plan: age, Pitt score, and presence of endocarditis. The incidences of events in secondary, safety, and subgroup analyses were compared using  $\chi^2$  test or Fisher exact test. The global benefits and risks of the combination therapy

were evaluated in a post hoc analysis using the approach of the Desirability of Outcome Ranking (DOOR) [29]. The components of this analysis were (1) death before TOC; (2) clinical or microbiological failure; and (3) premature discontinuation of therapy due to AEs or based on clinical judgment. All analyses were performed with a 2-sided significance level of .05 and conducted with the use of R software, version 3.5.

## RESULTS

From 16 December 2013 to 27 November 2017, we assessed 674 patients with MRSA bacteremia for eligibility, of whom 507 were not suitable for inclusion (Figure 1). A total of 167 patients were randomly assigned to receive daptomycin plus fosfomycin (82 patients) or daptomycin alone (85 patients). After excluding 12 patients who were randomized in error (5 patients) or did not receive the allocated study drug (7 patients) and consequently were excluded from the primary analysis population, the remaining 155 were included in the modified intention-to-treat population; 74 received daptomycin plus fosfomycin and 81 were given daptomycin alone.

Baseline characteristics of the patients were similar in the 2 treatment groups except for a higher number of patients with chronic kidney disease in the daptomycin alone group (Table 1). Echocardiography was performed in 112 (72%) patients, and a final diagnosis of left-side endocarditis was established in 18 (11.6%) patients in this subgroup. Overall, the median duration of antibiotic therapy since randomization was 14 days (interquartile range [IQR], 10–18 days) (Table 1).

Treatment success at TOC was achieved in 40 of 74 (54.1%) patients who received daptomycin plus fosfomycin and in 34 of 81 (42.0%) patients who were given daptomycin alone (relative risk, 1.29 [95% CI, .93–1.8];  $\chi^2$  test  $P = .133$ ) (Table 2 and Figure 2). Treatment failure at TOC occurred in 34 (45.9%) patients receiving daptomycin plus fosfomycin and in 47 (58%) receiving daptomycin alone ( $P = .133$ ). Reasons for treatment failure at TOC are detailed in Table 3. No cases of clinical or microbiological failure were observed in patients receiving daptomycin plus fosfomycin, whereas 12 patients receiving daptomycin alone had treatment failure (clinical in 3 and microbiological in 9 [0% vs 14.8%];  $P < .001$ ). More patients receiving daptomycin alone required the administration of nonstudy antibiotics active against MRSA before TOC than those treated with daptomycin plus fosfomycin (23.4% vs 12.1%;  $P = .068$ ).

Subgroup analyses suggested that patients aged <73 years and those with a Pitt score >1 could particularly benefit from receiving the combination of daptomycin plus fosfomycin to achieve treatment success at TOC. No differences were observed in patients with or without endocarditis (Figure 2).


The results for secondary endpoints are shown in Table 2 and Supplementary Figure 3. At day 3 of follow-up, daptomycin

plus fosfomycin was significantly associated with lower rates of positive blood cultures than daptomycin alone (2 of 74 patients [2.7%] vs 15 of 81 [18.5%], respectively). At day 7, 0 of 74 patients (0%) who received daptomycin plus fosfomycin vs 5 of 81 patients (6.2%) who received daptomycin alone had persistent bacteremia. Recurrent bacteremia from EOT to the TOC visit occurred in 0 of 74 (0%) patients receiving daptomycin plus fosfomycin vs 4 of 81 (3.7%) who received daptomycin alone. The final microbiological evaluation at TOC found that no patient treated with daptomycin plus fosfomycin had microbiological failure compared with 9 patients treated with daptomycin alone, among whom bacteremia was considered persistent in 5, and recurrent in 4 patients ( $P = .003$ ).

Development of resistance to daptomycin during treatment was documented in 1 patient with persistent bacteremia in the daptomycin alone group; the minimum inhibitory concentration increased from 0.5 mg/L to 2 mg/L. Among the 9 patients with microbiological failure, 6 had consecutive isolates available for pulsed-field gel electrophoresis typing. All pairs of isolates obtained from the same patient showed the same band pattern, and so microbiological failure was considered as a relapse.

Complicated bacteremia at TOC was observed in 12 of 74 patients (16.2%) who had received daptomycin plus fosfomycin and in 26 of 81 (32.1%) who had received daptomycin alone (relative risk, 0.51 [95% CI, .28–.94];  $\chi^2$  test  $P = .022$ ). No significant differences in overall mortality were observed at TOC between patients receiving daptomycin plus fosfomycin and those receiving daptomycin alone (24.3% vs 27.2%;  $P = .687$ ).

Patients receiving daptomycin plus fosfomycin had a higher rate of AEs leading to discontinuation of therapy than patients receiving daptomycin alone (17.6% vs 4.9%;  $P = .012$ ) (Table 4). No differences were observed between the groups at TOC in terms of overall mortality, lack of blood cultures, or loss to follow-up. A total of 103 AEs was recorded in 160 randomized patients who received any dose of study drug (Supplementary Table 5). The number of patients with AEs and serious AEs did not vary between the groups, but there were differences in the frequency of AEs related to the study drugs. The most frequent serious AEs in patients receiving daptomycin plus fosfomycin were cardiac failure in 5 cases and hypokalemia in 2. A 10-fold increase in creatinine phosphokinase values was observed in 1 patient receiving daptomycin plus fosfomycin and in 2 patients receiving daptomycin alone. AEs leading to treatment discontinuation occurred in 13 of 77 patients (16.9%) receiving daptomycin plus fosfomycin and in 4 of 83 patients (4.8%) receiving daptomycin alone ( $P = .013$ ; Table 4). The median time from randomization to discontinuation of the antibiotic treatment due to serious AEs was 10 days (IQR, 4–14 days) in patients receiving daptomycin plus fosfomycin and 10.5 days (IQR, 10–11.5 days) in those given daptomycin alone.



**Figure 1.** Trial profile. \*Reasons for exclusion after randomization were as follows: patient randomized twice (n = 2); positive blood culture >72 hours before randomization (n = 3); patient received <1 day of antibiotic treatment (n = 3); protocol violation (n = 4).

When benefits and risks of the intervention were analyzed by the DOOR approach, the probability that a patient randomly assigned to daptomycin plus fosfomycin combination would have a better DOOR ranking than if assigned to daptomycin alone was 61.6% (95% CI, 60.4%–62.8%).

## DISCUSSION

In this randomized clinical trial, daptomycin plus fosfomycin provided a 12% higher rate of treatment success than daptomycin alone at 6 weeks after end of therapy for MRSA bacteremia, but

this difference did not reach statistical significance. Of note, the antibiotic combination therapy precluded microbiological failure and complicated bacteremia at TOC but was more often associated with AEs leading to treatment discontinuation. Our results suggest that daptomycin plus fosfomycin could be more effective than daptomycin alone in younger patients and in those with more severe disease, but this needs to be confirmed after further study. Our findings were reinforced by the DOOR post hoc analysis showing that patients randomly assigned to daptomycin plus fosfomycin combination would have a better

**Table 1. Characteristics of Patients at Baseline in the Modified Intention-to-Treat Population**

Characteristic	Daptomycin Plus Fosfomycin (n = 74)	Daptomycin Alone (n = 81)
Age, y, median (IQR)	74.0 (60.8–80.8)	72 (62.0–80.0)
Male sex	48 (64.9)	56 (69.1)
Charlson comorbidity index, median (IQR) <sup>a</sup>	3 (2–5)	4 (2–5.8)
Diabetes mellitus <sup>b</sup>	29 (30.3)	34 (41.9)
Diabetes mellitus with end organ damage <sup>b</sup>	13 (17.6)	18 (22.2)
Chronic kidney disease <sup>b</sup>	19 (25.7)	35 (43)
Congestive heart failure <sup>b</sup>	13 (17.6)	19 (23.4)
Malignancy <sup>b</sup>	18 (24.3)	16 (19.7)
Pitt score, mean (SD) <sup>c</sup>	1.15 (1.7)	1.22 (2.0)
Implants	20 (27.0)	27 (33.3)
Orthopedic	11 (14.9)	13 (16.0)
Pacemaker	8 (10.8)	4 (4.9)
Previous antibiotic therapy <sup>d</sup>	59 (79.7)	65 (80.2)
Acquisition		
Community-acquired	7 (9.4)	4 (4.9)
Nosocomial infection	36 (48.6)	35 (43.2)
Healthcare-associated	31 (41.8)	42 (51.8)
Main source of infection		
Intravascular catheter	31 (41.9)	39 (48.1)
Skin and soft tissue infection	10 (13.5)	19 (23.5)
Surgical site infection	7 (9.5)	4 (4.9)
Urinary tract infection	6 (8.1)	3 (3.7)
Unknown source	14 (18.9)	8 (9.9)
Other	6 (7.4)	8 (9.9)
Echocardiography	53 (71.6)	59 (72.8)
Endocarditis <sup>e</sup>	9 (12.2)	9 (11.1)
Days of therapy, median (IQR)	14 (11–21)	14 (10–18.5)

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: IQR, interquartile range; SD, standard deviation.

<sup>a</sup>Provides a 10-year mortality risk, based on weighted comorbid conditions.

<sup>b</sup>Based on the definitions within the Charlson comorbidity index assessment.

<sup>c</sup>Provides a measure of in-hospital mortality risk in patients with bloodstream infection based on clinical variables.

<sup>d</sup>Based on administration of any antibiotic in the 10 days prior to randomization.

<sup>e</sup>Based on assessment at test-of-cure visit according to modified Duke criteria [27].

**Table 2. Primary and Secondary Outcomes**

Outcome	Daptomycin Plus Fosfomycin, No. of Patients/Total (%)	Daptomycin Alone, No. of Patients/Total (%)	Relative Risk (95% CI)
Primary endpoint			
Treatment success at TOC	40/74 (54.1)	34/81 (42.0)	1.29 (.93–1.8)
Secondary endpoints			
Positive blood cultures at day 3	2/74 (2.7)	15/81 (18.5)	0.15 (.04–.63)
Positive blood cultures at day 7	0/74 (0.0)	5/81 (6.2)	–6.2 (–11.4 to –.9) <sup>a</sup>
Positive blood cultures at TOC	0/74 (0.0)	4/81 (4.9)	–4.9 (–9.7 to –.2) <sup>a</sup>
Microbiological failure at TOC	0/74 (0.0)	9/81 (11.1)	–11.1 (–18.0 to –4.3) <sup>a</sup>
No. of episodes of complicated bacteremia at TOC	12/74 (16.2)	26/81 (32.1)	0.51 (.28–.94)
Any AE leading to treatment discontinuation	13/74 (17.6)	4/81 (4.9)	3.56 (1.21–10.44)
Overall mortality at day 7	3/74 (4.1)	6/81 (7.4)	0.55 (.14–2.12)
Overall mortality at TOC	18/74 (24.3)	22/81 (27.2)	0.9 (.53–1.54)

Abbreviations: AE, adverse event; CI, confidence interval; TOC, test of cure.

<sup>a</sup>Proportion difference, as it was not possible to estimate the relative risk.




Figure 2. Primary endpoint.

DOOR ranking, and thus a better outcome, than if assigned to daptomycin alone.

We found that no patient receiving daptomycin plus fosfomycin had persistent bacteremia at day 7 and/or relapsing

bacteremia at TOC. Rapid clearance of MRSA bacteremia is an important target, since the persistence of positive blood cultures beyond day 3 has been closely related to worse clinical outcomes [30, 31]. Importantly, we found that patients receiving

Table 3. Reasons for Treatment Failure at Test of Cure

Reason for Treatment Failure	Daptomycin Plus Fosfomycin, No. (%) of Patients (n = 74)	Daptomycin Alone, No. (%) of Patients (n = 81)	Proportion Difference (95% CI)	P Value <sup>a</sup>
Treatment failure <sup>b</sup>	34 (45.9)	47 (58.0)	-12.1 (-27.7 to 3.6)	.133
Mortality at TOC	18 (24.3)	22 (27.1)	-2.8 (-16.6 to 10.9)	.687
Clinical failure <sup>c</sup>	0 (0.0)	3 (3.7)	-3.7 (-7.8 to .4)	.247 <sup>d</sup>
Microbiological failure	0 (0.0)	9 (11.1)	-11.1 (-18.0 to -4.3)	.003 <sup>d</sup>
Any AE leading to treatment discontinuation	13 (17.6)	4 (4.9)	12.6 (2.8-22.5)	.012
Additional antimicrobial therapy administered before TOC <sup>e</sup>	9 (12.1)	19 (23.4)	-11.3 (-23.2 to .6)	.068
Lack of blood cultures at TOC	8 (10.8)	4 (4.9)	5.9 (-2.6 to 14.4)	.172
Loss to follow-up	1 (1.3)	3 (3.7)	-2.4 (-7.2 to 2.5)	.622 <sup>d</sup>

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: AE, adverse event; CI, confidence interval; TOC, test of cure.

<sup>a</sup>Unless otherwise specified, P value derived from  $\chi^2$  test.

<sup>b</sup>Patients might have >1 reason for treatment failure (ie, mortality at TOC, clinical or microbiological failure, any AE leading to treatment discontinuation, additional antimicrobial therapy administered before TOC, lack of blood cultures before TOC).

<sup>c</sup>Lack of clinical improvement  $\geq 3$  days after the start of therapy.

<sup>d</sup>Fisher exact test.

<sup>e</sup>Receipt of potentially effective nonstudy antibiotics active against methicillin-resistant *Staphylococcus aureus* before TOC visit.

**Table 4. Adverse Events Leading to Treatment Discontinuation**

Adverse Event	Daptomycin Plus Fosfomycin (n = 77)	Daptomycin Alone (n = 83)	Relation to Antibiotic Treatment
Patients with AE leading to treatment discontinuation, No. (%)	13 (16.9)	4 (4.8)	...
AE leading to treatment discontinuation, No. (%)	16 (20.8)	4 (4.8)	...
Cardiac failure, No.	4	...	R
Hypokalemia (<3 mmol/L), No.	2	...	R
Hypocalcemia (corrected serum total calcium level <2.12 mmol/L), No.	1	...	R
Acute renal failure, No.	1	1	NR
Creatinine phosphokinase increase (>10-fold), No.	1	1	R
Respiratory failure, No.	...	1	NR
Respiratory tract infection, No.	2	1	NR
Acute liver injury, No.	1	...	NR
Severe acute digestive bleeding, No.	1	...	NR
Nausea/vomiting, No.	2	...	R

Abbreviations: AE, adverse event; NR, nonrelated; R, related.

combination therapy developed complicated bacteremia less often and that no antibiotic resistance occurred in any patients in this group. Our results concur with those reported in small series of patients treated with  $\beta$ -lactams or daptomycin plus fosfomycin [23, 24]. Additionally, the combination of daptomycin plus fosfomycin might prevent the emergence of drug resistance. The single patient who developed resistance to daptomycin was receiving daptomycin alone.

We found that AEs leading to treatment discontinuation were more frequent in patients receiving daptomycin plus fosfomycin. The antibiotic combination was more often associated with cardiac failure and electrolyte disorders, particularly hypokalemia and hypocalcemia. It has been suggested that hypokalemia could be avoided in some cases by the extended infusion of fosfomycin over a 4-hour period [32]. The fact that fosfomycin-related serious AEs appeared after a median of 10 days of therapy and the high microbiological efficacy achieved at 3 and 7 days of the combination therapy suggest that fosfomycin should essentially be administered during the first week of treatment.

Our randomized trial has several limitations. The study was not blinded for the investigators, and this might have impact decisions to discontinue the therapy due to clinical worsening or suspected AE. The effect of this potential bias was minimized by including microbiological analyses in the treatment success definition. Furthermore, the study was performed in a single country and this might have limited the generalizability of our results.

In conclusion, daptomycin plus fosfomycin provided a 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. Our results suggest that this antibiotic combination could be more effective in younger patients and those with more severe disease. Daptomycin plus fosfomycin precluded microbiological failure and complicated bacteremia but was more often associated with AEs leading to treatment discontinuation.

### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Acknowledgments.** The authors thank the study collaborators from all of the centers that participated in the MRSA Bacteremia (BACSARM) trial: Alex Soriano, PhD, and Manel Almela, PhD (Hospital Clinic, Barcelona, Spain); Frederic Gómez, MD (Hospital Joan XXIII, Tarragona, Spain); Fernando Chávez, PhD (Hospital 12 Octubre, Madrid, Spain); Beatriz Mirelis, PhD (Hospital Santa Creu i Sant Pau, Barcelona, Spain); Emma Padilla, MD (Catlab–Hospital de Terrassa, Terrassa, Spain); Maria Dolores Pérez-Ramírez, MD (Hospital Virgen de las Nieves, Granada, Spain); Mateu Espasa, MD (Hospital del Parc Taulí, Sabadell, Spain); Ana Maria Sánchez-Díaz (Hospital Ramón y Cajal, Madrid, Spain); Emilia Cercenado, PhD (Hospital Gregorio Marañón, Madrid, Spain); Enrique Ruiz de Gopegui, PhD (Son Espases, Mallorca, Spain); Ana Siverio (Hospital del Mar, Barcelona, Spain); Marina de Cueto, PhD (Hospital Virgen de la Macarena, Sevilla, Spain); Fernando García-Garrote (Hospital Lucus Augusti, Lugo, Spain); Mercè Garcia (Hospital Arnau de Vilanova, Lleida, Spain); Mariona Xercavins (Hospital Mútua de Terrassa, Terrassa, Spain); and Maria Nieves Larrosa, PhD (Hospital Vall Hebron, Barcelona, Spain).

**Disclaimer.** The study's funders were not involved in the study design, data interpretation or analysis, or the revision of the final report. The corresponding author had full access to all study data and had final responsibility for the decision to submit the paper for publication.

**Financial support.** This work was supported by the Spanish Ministry of Science, Innovation and Universities (PI12/01907); Spanish Network for Research in Infectious Diseases (RD16/0016/0005); Instituto de Salud Carlos III (ISCIII); and Spanish Ministry of Economy, Industry and Competitiveness. This work was also supported by the European Development Regional Fund "A way to achieve Europe," Operational Programme Intelligent Growth 2014–2020; Spanish Clinical Research Network (SCReN), co-financed by the Plan Nacional de I+D and ISCIII, Subdirección General de Evaluación y Fomento de la Investigación (PT13/0002/0007); and the Grupo de Estudio de la Infección Relacionada con la Asistencia Sanitaria. J. M.-M. received a personal 80:20 research grant from the Institut d'Investigacions Biomèdiques Agust Pi i Sunyer, Barcelona, Spain, during 2017–2021.

**Potential conflicts of interest.** The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.



## References

1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. *N Engl J Med* **2009**; 360:439–43.
2. Gasch O, Camoez M, Dominguez MA, et al; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant *Staphylococcus aureus* bloodstream infection: impact on outcome of host, microorganism and therapy. *Clin Microbiol Infect* **2013**; 19:1049–57.
3. Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States. *Clin Infect Dis* **2019**; 69:2112–8.
4. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to *Staphylococcus aureus*: subset analysis of patients infected with methicillin-resistant isolates. *J Antimicrob Chemother* **2008**; 62:1413–21.
5. Gasch O, Ayats J, Angeles Dominguez M, et al. Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. *Medicine (Baltimore)* **2011**; 90:319–27.
6. Bassetti M, Peghin M, Trearichi EM, et al. Characteristics of *Staphylococcus aureus* bacteraemia and predictors of early and late mortality. *PLoS One* **2017**; 12:e0170236.
7. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* **2011**; 52:e18–55.
8. Levine DP. Vancomycin: a history. *Clin Infect Dis* **2006**; 42(Suppl 1):S5–12.
9. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with *Staphylococcus aureus* bloodstream infections: a systematic review and meta-analysis. *JAMA* **2014**; 312:1552–64.
10. Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE). *Clin Infect Dis* **2020**; 70:1536–45.
11. Davis JS, Sud A, O'Sullivan MVN, et al. Combination of vancomycin and  $\beta$ -lactam therapy for methicillin-resistant *Staphylococcus aureus* bacteremia: a pilot multicenter randomized controlled trial. *Clin Infect Dis* **2016**; 62:173–80.
12. Tong SYC, Lye DC, Yahav D, et al; Australasian Society for Infectious Diseases Clinical Research Network. Effect of vancomycin or daptomycin with vs without an antistaphylococcal  $\beta$ -lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia. *JAMA* **2020**; 323:527–37.
13. Thwaites GE, Scarborough M, Szubert A, et al; United Kingdom Clinical Infection Research Group. Adjunctive rifampicin for *Staphylococcus aureus* bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* **2018**; 391:668–78.
14. Fowler VG Jr, Boucher HW, Corey GR, et al; *S. aureus* Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* **2006**; 355:653–65.
15. Gasch O, Camoez M, Dominguez MA, et al; REIPI/GEIH Study Groups. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant *Staphylococcus aureus* persistent bacteraemia treated with daptomycin. *J Antimicrob Chemother* **2014**; 69:568–71.
16. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomicin. *Clin Microbiol Rev* **2016**; 29:321–47.
17. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. *Clin Microbiol Rev* **2013**; 26:759–80.
18. Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ. Resistance to fosfomicin: mechanisms, frequency and clinical consequences. *Int J Antimicrob Agents* **2019**; 53:22–8.
19. del Río A, García-de-la-María C, Entenza JM, et al. Fosfomicin plus  $\beta$ -lactams as synergistic bactericidal combinations for experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2016**; 60:478–86.
20. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE.  $\beta$ -Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2013**; 57:5005–12.
21. Gasch O, Pillai SK, Dakos J, Miyakis S, Moellering RC Jr, Eliopoulos GM. Daptomycin in vitro activity against methicillin-resistant *Staphylococcus aureus* is enhanced by d-cycloserine in a mechanism associated with a decrease in cell surface charge. *Antimicrob Agents Chemother* **2013**; 57:4537–9.
22. García-de-la-María C, Gasch O, García-Gonzalez J, et al. The combination of daptomycin and fosfomicin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant *Staphylococcus aureus* in a rabbit model of experimental endocarditis. *Antimicrob Agents Chemother* **2018**; 62:e02633-17.
23. del Río A, Gasch O, Moreno A, et al; FOSIMI Investigators. Efficacy and safety of fosfomicin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant *Staphylococcus aureus*: a multicenter clinical trial. *Clin Infect Dis* **2014**; 59:1105–12.
24. Miró JM, Entenza JM, Del Río A, et al; Hospital Clinic Experimental Endocarditis Study Group. High-dose daptomycin plus fosfomicin is safe and effective in treating methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* **2012**; 56:4511–5.
25. Shaw E, Miró JM, Puig-Asensio M, et al; Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); Instituto de Salud Carlos III, Madrid, Spain; GEIH (Hospital Infection Study Group). Daptomycin plus fosfomicin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. *BMJ Open* **2015**; 5:e006723.
26. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* **1995**; 33:2233–9.
27. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* **2000**; 30:633–8.
28. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice. Current step 4 version. **1996**. Available at: <https://apps.who.int/medicinedocs/documents/s22154en/s22154en.pdf>. Accessed 15 January 2020.
29. Doernberg SB, Tran TTT, Tong SYC, et al; Antibacterial Resistance Leadership Group. Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for *Staphylococcus aureus* bloodstream infection. *Clin Infect Dis* **2019**; 68:1691–8.
30. Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of *Staphylococcus aureus* bacteremia predictive of poor outcomes. *Clin Infect Dis* **2019**; 70:566–73.
31. López J, Sevilla T, Vilacosta I, et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. *Eur Heart J* **2013**; 34:1749–54.
32. Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomicin. *Int J Antimicrob Agents* **2011**; 37:82–3.